Skip to content

HIV treatment isn't a risk factor for liver dysfunction, but HIV infection is

Hepatitis C protease inhibitor therapy cost-effective in some circumstances

Hepatitis C surpasses HIV as a cause of death in the US

Professional tattooing in sterile environment not associated with risk of hepatitis C

Studies from US and Spain show that hepatitis vaccination programmes not reaching target populations

Common side-effects of hepatitis C protease inhibitors: clinical management advice published

Early guidance on use of hepatitis C protease inhibitors in HIV-co-infected patients

Co-infection with hepatitis B worsens HIV-related outcomes

Hepatitis B genotype B associated with poorer liver-related outcomes in Taiwanese patients co-infected with HIV and hepatitis B